It remains challenging to build de novo sterile manufacturing capacity given the timelines. As you stated. the US will need to utilise all necessary tools to reshore manufacturing but I would be interested in understanding how much progress has been made in continuous manufacturing of late.
It remains challenging to build de novo sterile manufacturing capacity given the timelines. As you stated. the US will need to utilise all necessary tools to reshore manufacturing but I would be interested in understanding how much progress has been made in continuous manufacturing of late.